The Best Peptides for Weight Loss: GLP-1 Agonists, AOD-9604, Adipotide, and the Full Picture
The peptide weight loss landscape spans from the most clinically validated drugs in pharmaceutical history to the most experimental compounds in research. This guide covers the full spectrum — mechanisms, clinical data, dosing protocols, and honest risk assessment — so researchers can navigate it with clarity.
For Educational & Research Purposes Only
This article is an educational resource. Nothing here constitutes medical advice. Some compounds discussed are experimental with limited human safety data. Always consult a licensed healthcare provider before beginning any peptide protocol.
How Peptides Target Fat Loss
Peptides approach fat loss through several distinct mechanisms: appetite suppression and satiety signaling (GLP-1 agonists), direct lipolysis at the adipocyte level (AOD-9604, GH fragments), adipose vasculature disruption (Adipotide), and systemic growth hormone elevation (Tesamorelin). These mechanisms are not mutually exclusive — the most sophisticated fat loss protocols layer multiple approaches to address intake, expenditure, and adipose-specific signaling simultaneously.
The GLP-1 agonist revolution has been the defining story in obesity medicine over the past five years. But it is not the complete story. Understanding what GLP-1s do — and do not do — helps researchers identify where complementary peptides add meaningful value.
Peptide Profiles
Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist — the same mechanism as Ozempic and Wegovy. GLP-1 is an incretin hormone released from the gut after eating; it slows gastric emptying, reduces appetite via hypothalamic signaling, increases insulin secretion, and reduces glucagon release. Semaglutide has demonstrated remarkable efficacy in clinical trials, with the STEP program showing average weight loss of 14.9% of body weight at 68 weeks. It is currently the gold standard GLP-1 agonist for weight management, with the most robust clinical data of any peptide in this category.
Typical Research Dosing
Start at 0.25 mg subcutaneous weekly for 4 weeks, titrating up by 0.25 mg every 4 weeks to a target of 1–2.4 mg weekly. Slow titration significantly reduces GI side effects.
- Average 14.9% body weight reduction in STEP trials at 2.4 mg/week
- Reduces appetite centrally and slows gastric emptying — dual mechanism
- Also demonstrated cardiovascular protection (SELECT trial: 20% CV event reduction)
- Compounded access is regulated in the US — availability varies by jurisdiction
Tirzepatide (Mounjaro, Zepbound) is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. The addition of GIP receptor activity appears to meaningfully enhance efficacy beyond GLP-1 agonism alone — the SURMOUNT trials demonstrated average weight loss of 20.9% at the highest dose (15 mg), with some participants achieving 25%+ body weight reduction. GIP also has additional effects on adipose tissue directly, reducing fat storage efficiency. Tirzepatide currently holds the strongest clinical efficacy data of any weight loss peptide — and likely of any pharmaceutical weight loss agent studied to date.
Typical Research Dosing
Start at 2.5 mg subcutaneous weekly, titrating by 2.5 mg every 4 weeks to a target of 5–15 mg weekly.
- Average 20.9% body weight loss at 15 mg/week in SURMOUNT-1 trial
- Dual GIP + GLP-1 mechanism — GIP adds direct adipose tissue effects
- Cardiovascular outcomes trial (SURMOUNT-MMO) shows significant benefit
- Compounded access became restricted in 2025 following shortage resolution
Retatrutide is the next generation beyond tirzepatide — a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. The glucagon receptor component significantly increases energy expenditure (thermogenesis), which adds a caloric-burning dimension not seen in GLP-1 or dual agonists. Phase 2 trials showed average weight loss of 24.2% at 48 weeks, with continued downward trends suggesting even greater loss with longer treatment. It remains in Phase 3 trials as of 2026 and is not yet commercially available — but represents where GLP-1-class therapy is heading.
Typical Research Dosing
Phase 2 dosing: 1 mg, 4 mg, 8 mg, or 12 mg subcutaneous weekly. Not yet standardized for research use.
- Triple agonism: GIP + GLP-1 + glucagon — adds energy expenditure to appetite suppression
- Phase 2 data shows 24.2% weight loss at 48 weeks — exceeding tirzepatide timelines
- Phase 3 enrollment ongoing as of 2026 — not yet commercially available
- Glucagon agonism may increase basal metabolic rate significantly
AOD-9604 is a synthetic peptide fragment of human growth hormone (amino acids 176–191) that retains growth hormone's lipolytic (fat-breaking) properties while eliminating its anabolic and insulin-sensitizing effects. It works by stimulating lipolysis — the breakdown of stored fat — specifically in adipose tissue, without significantly elevating blood glucose or IGF-1. Unlike GLP-1 agonists that reduce caloric intake, AOD-9604 directly targets fat cells and promotes their breakdown. This makes it particularly useful as an adjunct to GLP-1 protocols or for researchers looking for a non-appetite-suppressing fat loss approach.
Typical Research Dosing
300–500 mcg subcutaneous, once daily, ideally in a fasted state in the morning.
- Targets lipolysis specifically — breaks down stored fat without affecting muscle mass
- Does not elevate IGF-1 or cause glucose dysregulation like full GH
- FDA-approved for safety in human trials (investigated for oral obesity treatment)
- Pairs well with GLP-1 agonists for multi-mechanism fat loss
Adipotide (also known as FTPP — fatty tissue-targeting pro-apoptotic peptide) is an experimental peptide that takes a fundamentally different approach to fat loss: rather than modulating appetite or metabolism, it directly targets and destroys the blood vessels supplying adipose tissue, causing adipocytes (fat cells) to undergo apoptosis (programmed cell death). In primate studies, Adipotide produced 11% body weight loss in 28 days — primarily from adipose tissue — without changes to diet. It is one of the most potent fat-loss compounds in research, but it is highly experimental, with significant renal toxicity concerns noted in primate studies that have prevented human clinical trials. This compound requires exceptional caution and thorough risk evaluation.
Typical Research Dosing
Primate research dosing: 56 mcg/kg subcutaneous daily for 28 days. Human dosing protocol has not been established — this remains a strictly experimental compound.
- Primate studies: 11% body weight loss in 28 days from adipose tissue destruction
- Mechanism is irreversible at the site of action — destroyed fat cells do not regenerate
- Renal toxicity was observed in primate trials — significant safety concern
- No human clinical trials conducted — treat as high-risk experimental only
While best known for muscle growth applications, Tesamorelin has a uniquely specific FDA-approved indication for visceral adiposity reduction in HIV-associated lipodystrophy. Its clinical data demonstrates significant reductions in visceral abdominal fat — the metabolically active, health-impacting fat around internal organs — by stimulating endogenous growth hormone secretion. GH is a known lipolytic hormone that specifically targets visceral adipose tissue. For researchers dealing with visceral fat specifically (as opposed to subcutaneous fat), Tesamorelin is one of the few peptides with direct, randomized clinical trial evidence of visceral fat reduction in humans.
Typical Research Dosing
1–2 mg subcutaneous daily, typically before bed.
- FDA-approved indication for visceral fat reduction (HIV lipodystrophy)
- Clinical trials demonstrate significant visceral adiposity reduction vs. placebo
- Targets visceral fat specifically — the metabolically harmful abdominal fat
- Combines well with AOD-9604 for both visceral and subcutaneous fat coverage
Building a Weight Loss Protocol
GLP-1 Agonists: The Appetite Suppression Layer
Semaglutide and tirzepatide address the intake side of the energy equation — reducing caloric consumption through appetite suppression, slowed gastric emptying, and hypothalamic signaling. They are the most clinically validated options for meaningful weight loss and represent the appropriate first-line peptide approach for most researchers. Tirzepatide's dual mechanism gives it an efficacy edge; semaglutide has more long-term data.
AOD-9604: The Expenditure Layer
AOD-9604 works independently of appetite — it promotes lipolysis directly at the adipose tissue level. This makes it a valuable adjunct to GLP-1 protocols, targeting fat breakdown while GLP-1 reduces input. For researchers who want to optimize both sides of the energy equation simultaneously, pairing a GLP-1 agonist with AOD-9604 represents a multi-mechanism approach.
Tesamorelin for Visceral Fat Specifically
Not all body fat responds equally to the same protocols. Visceral fat — the fat stored around internal organs — is particularly responsive to GH-driven lipolysis but less responsive to caloric restriction alone. For researchers with a specific visceral fat concern, Tesamorelin addresses this compartment more directly than GLP-1 agonists alone.
Adipotide: Understanding the Research
Adipotide represents the most extreme end of fat-loss research — a compound that destroys adipose vasculature rather than modulating metabolism. The primate efficacy data is dramatic; the renal toxicity data demands serious consideration. This compound is included here for research education purposes. It should not be approached without thorough due diligence and professional medical oversight.
Other Articles
Calculator
Calculate exact reconstitution volumes and insulin unit doses for any peptide protocol.
Open Calculator →